Overview

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
Phase:
Phase 3
Details
Lead Sponsor:
Sage Therapeutics